[Hit News] StemExOne and ExoCalibur Sign Research Agreement to Develop Exosome Therapeutics

From left: Tae-hyung Kim, CEO of ExoCalibur, and Ssang-Goo Cho, CEO of StemExOne, signed an MOU for joint research on the development of exosome therapeutics.

StemExOne Conducts Government-Funded R&D Projects on Stem Cell-Derived Exosome Therapeutics
ExoCalibur Holds Patents for Therapeutic Cargo Loading Technologies in Exosomes

[Hit News] StemExOne, a subsidiary of Konkuk University Holdings led by CEO Ssang-Goo Cho, and ExoCalibur, a subsidiary of Chosun University Holdings led by CEO Tae-hyung Kim, announced that they have signed a memorandum of understanding (MOU) to conduct joint research on the development of exosome therapeutics.

Exosomes are gaining attention as a promising alternative capable of overcoming several limitations of conventional cell therapies, including concerns related to side effects and safety. Through the agreement, StemExOne and ExoCalibur plan to combine and share their respective expertise in exosome research to advance the development of exosome-based therapeutics.

Founded in 2020, StemExOne is carrying out multiple government-funded R&D projects related to stem cell-derived exosome therapeutics, including projects supported by the Korea Regenerative Medicine Fund (KFRM) and TIPS. ExoCalibur, also founded in 2020, holds patents covering technologies for loading therapeutic cargo into exosomes.

Ssang-Goo Cho, CEO of StemExOne, said, “Many companies are working toward the clinical development of exosome therapeutics, but innovative technologies are still needed to address the challenges of large-scale exosome production and heterogeneity. Through this MOU, we intend to accelerate the development of highly advanced exosome therapeutics.”

Tae-hyung Kim, CEO of ExoCalibur, said, “We believe exosomes have the potential to serve as highly effective therapeutic delivery vehicles of the future. Through our joint research, we expect to shorten exosome production times and develop technologies capable of loading large quantities of proteins, nucleic acids, and drugs into exosomes, thereby enabling the large-scale production of highly homogeneous exosomes.”

Source: Hit News